Parkinson'
Conditions
Interventions
reduced form of CoQ10 300mg 16weeks
reduced form of CoQ10 600mg 16weeks
reduced form of CoQ10 600mg 16weeks hydrogen water 500ml(Suisosui 7.0) 16weeks
Sponsors
Juntendo University Koshigaya Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: diagnosed as PD conforming to the United Kingdom Brain Bank criteria treated with levodopa the same anti-parkinsonian drug regimen for at least 8 weeks prior to baseline assessment modified Hoehn and Yahr stage 1~3 twenty to eighty years old without dementia written informed consent was obtained
Exclusion criteria
Exclusion criteria: presence of parkinsonism unrelated to PD, dementia or other serious disease, malignant tumor, a history of brain surgery, and adverse events caused by medications. modified Hoehn and Yahr stage 4 and 5 without allergy for medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The differences from baseline to 16th week of MDS-UPDRS part III and plasma % coenzyme Q10(CoQ10) | — |
Secondary
| Measure | Time frame |
|---|---|
| The differences of each parts or total of MDS-UPDRS The differences of urine 18OH-dG The differences of plasma reduced form of CoQ10 | — |
Countries
Japan
Contacts
Public ContactAsako Yoritaka
Neurology Juntendo University Koshigaya Hospital
Outcome results
None listed